These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29609511)

  • 41. Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension.
    Hopper RK; Ivy DD; Yung D; Mullen MP; Hanna BD; Kirkpatrick E; Hirsch R; Austin ED; Fineman J; Solum D; Deng CQ; Feinstein JA
    J Cardiovasc Pharmacol; 2020 Jul; 76(1):94-100. PubMed ID: 32398473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
    Chakinala MM; Feldman JP; Rischard F; Mathier M; Broderick M; Leedom N; Laliberte K; White RJ
    J Heart Lung Transplant; 2017 Feb; 36(2):193-201. PubMed ID: 27469018
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
    McLaughlin VV; Palevsky HI
    Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
    Voswinckel R; Reichenberger F; Enke B; Kreckel A; Krick S; Gall H; Schermuly RT; Grimminger F; Rubin LJ; Olschewski H; Seeger W; Ghofrani HA
    Pulm Pharmacol Ther; 2008 Oct; 21(5):824-32. PubMed ID: 18657627
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of Treprostinil on the Early Postoperative Prognosis of Patients with Severe Left Heart Valvular Disease Combined with Severe Pulmonary Hypertension.
    Huang ST; Xu N; Sun KP; Chen Q; Cao H
    Ann Thorac Cardiovasc Surg; 2021 Feb; 27(1):18-24. PubMed ID: 32493870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treprostinil for the treatment of pulmonary hypertension.
    Skoro-Sajer N; Lang I
    Expert Opin Pharmacother; 2008 Jun; 9(8):1415-20. PubMed ID: 18473715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treprostinil for pulmonary hypertension.
    Skoro-Sajer N; Lang I; Naeije R
    Vasc Health Risk Manag; 2008; 4(3):507-13. PubMed ID: 18827901
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.
    Krishnan U; Takatsuki S; Ivy DD; Kerstein J; Calderbank M; Coleman E; Rosenzweig EB
    Am J Cardiol; 2012 Dec; 110(11):1704-9. PubMed ID: 22917554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
    Mathier MA; McDevitt S; Saggar R
    J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension.
    Ferrantino M; White RJ
    Expert Opin Pharmacother; 2011 Nov; 12(16):2583-93. PubMed ID: 21988216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
    Suleman N; Frost AE
    Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment.
    Peterson L; Marbury T; Marier J; Laliberte K
    J Clin Pharm Ther; 2013 Dec; 38(6):518-23. PubMed ID: 24033615
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral treprostinil diethanolamine for pulmonary arterial hypertension.
    Feldman J; Im Y; Gill K
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):55-60. PubMed ID: 25409915
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral treprostinil in the treatment of pulmonary arterial hypertension.
    Feldman J; Habib N; Radosevich J; Dutt M
    Expert Opin Pharmacother; 2017 Oct; 18(15):1661-1667. PubMed ID: 28922964
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhaled treprostinil and pulmonary arterial hypertension.
    Nadler ST; Edelman JD
    Vasc Health Risk Manag; 2010 Dec; 6():1115-24. PubMed ID: 21191432
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
    Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    Poms A; Kingman M
    Crit Care Nurse; 2011 Dec; 31(6):e1-10. PubMed ID: 22135338
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension.
    Sarangarm P; Elwood K
    Am J Health Syst Pharm; 2021 Nov; 78(23):2110-2115. PubMed ID: 34100906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension.
    Ataya A; Somoracki A; Cope J; Alnuaimat H
    Pulm Pharmacol Ther; 2016 Oct; 40():39-43. PubMed ID: 27470680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
    Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.